We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Gene Therapy Cures Heart Disorder in Mouse Model

By Biotechdaily staff writers
Posted on 23 Aug 2006
Researchers have identified a subtype of the adeno-associated virus (AAV) that is 200 times more potent in its ability to penetrate cardiac tissue, and have demonstrated its potential for use in gene therapy by successfully treating a mouse model for Pompe disease. More...


Pompe disease (also called glycogen storage disease type II or acid maltase deficiency) is a rare genetic disorder caused by a deficiency in the enzyme acid alpha-glucosidase (GAA), which is needed to break down glycogen. It is the only glycogen storage disease with a defect in lysosomal metabolism and was the first glycogen storage disease to be identified.

The build-up of glycogen causes progressive muscle weakness throughout the body and affects various body tissues, particularly in the heart, skeletal muscles, liver, and nervous system. Transmission is by autosomal recessive inheritance. Children have a one in four chance of inheriting the disease when both parents carry the abnormal gene. It is estimated to occur in about one in 40,000-300,000 births.

Investigators at the University of Florida (Gainesville, USA) evaluated several different sub-types of AAV as potential vectors for gene therapy of congenital heart diseases. They found that the AAV-9 subtype was taken up throughout the heart muscle at 200 times the levels achieved with the previously used AAV-1 subtype. None of the AAV subtypes tested were found to cause disease or trigger a major immune system reaction.

The AAV-9 vector was loaded with the gene for GGA that is lacking in Pompe disease and then injected into animals in a mouse model for the syndrome. Results published in the July 27, 2006, online edition of Circulation Research revealed that the gene therapy eliminated symptoms of the disease.

"Right now AAV-9 seems to be our best solution for heart problems,” said senior author Dr. Barry J. Byrne, professor of pediatric cardiology at the University of Florida. "This is a way of delivering gene therapy to the heart that is aimed at treating genetic diseases affecting the heart. It is efficient and long lasting. One of the other distinguishing features of our research is that it is probably the first to demonstrate a physiologic correction of a genetic cardiac abnormality.”



Related Links:
University of Florida

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.